about
Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer.Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.Utility of an immunoglobulin gene rearrangement assay based on multiplex PCR in detecting bone marrow involvement in B-cell non-Hodgkin lymphoma.A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma.The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by LymphomaMinimal Clinically Important Difference in the Physical, Emotional, and Total Symptom Distress Scores of the Edmonton Symptom Assessment System.A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients.Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.Overcoming barriers in cancer pain management.Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns and Outcomes in Very Elderly Patients with Diffuse Large B-cell Lymphoma: The Korean Cancer Study Group LY16-01.A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics.Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.Induction of cytotoxic T lymphocytes by dendritic cells pulsed with murine leukemic cell RNA.Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma.Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer.Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT.Is spirituality related to survival in advanced cancer inpatients in Korea?Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea.Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study.Randomized Phase III Trial of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.Adopting Advance Directives Reinforces Patient Participation in End-of-Life Care Discussion.Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL).Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer.Attitudes toward early palliative care in cancer patients and caregivers: a Korean nationwide survey.Surrogate decision making of chemotherapy consent: do we really provide informed consent of chemotherapy for patients?Priorities of a "good death" according to cancer patients, their family caregivers, physicians, and the general population: a nationwide surveySpiritual Well Being Among Palliative Care Patients with Different Religious Affiliations: A Multicenter Korean StudyComparison of attitudes towards five end-of-life care interventions (active pain control, withdrawal of futile life-sustaining treatment, passive euthanasia, active euthanasia and physician-assisted suicide): a multicentred cross-sectional survey ofInvestigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell CarcinomaClinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study
P50
Q33366910-9F79D388-C1AB-4E64-ACB5-0347C444DE08Q33382841-FE2A799A-CE9D-47EB-9A19-1BFF4D04AB01Q33402605-4D555F62-253B-4619-9739-20216E7935FAQ33406952-D86F6582-01CE-4966-8C22-73A27BD15127Q33420043-5355521F-88A4-4695-993C-5AB06C73CAA1Q33889968-8C79A06A-B650-4E8C-BD8F-5B4E2D53A5DDQ34491238-69B56104-C3E9-4C53-AE68-F248BFBEB469Q35862357-CB76E4DB-F52F-4E29-8EB3-9BD8AF22CEA4Q36522629-84420026-EF66-4517-A9A0-4B850FC1D7CAQ37245902-0D3F5CC1-0359-404C-8EB4-74CA254A186CQ37687767-09A4C8BF-2D56-4271-BD42-A4BE17946984Q38209639-1E25A838-8968-4B89-93E3-B940FFF5AD49Q38731955-0246F448-C712-4B2D-BD77-C1EAFAB9F9ACQ39217581-20D72104-CC90-45F7-8F28-50C79A9B3579Q40419170-EB31EBC5-376B-4767-BD5A-FA16F2F412D7Q40586944-83FFACE8-5E50-422E-AA7D-253BE9F2BBCCQ40696762-193982FB-1B70-49A7-8973-CE28D488FAFBQ43187600-F6E1FC37-90AF-417A-8449-14BC85F60556Q44664897-5354178D-247F-446D-9CB7-7324989D1A12Q45041047-04B6B933-D551-4405-A708-A5CAE308BF8DQ45530965-CDB9CD32-8840-4248-9DEB-DCE3D17235F9Q46134832-2C993F0C-CFE0-4D3E-8A99-18B45A599999Q46235757-E7C393CE-4685-4D1E-B4F0-61CEE6D08AD3Q47196540-68628672-F4BF-4354-B4AA-404D50AE1323Q47562096-95F291F9-5EF2-46A8-9239-7BDB469C0F1BQ48344983-FCD21B05-2928-421A-A9E8-128D21AF935DQ52632723-F1C8179E-2FAD-4F59-A4F6-E95BAC5537F8Q52727114-F3975D1C-2907-4F49-8817-1520C79ACB97Q53302316-684E137D-FF01-4867-854E-CFA205BC3E04Q53357340-4FE59465-7369-422D-BD4A-EE2A678EC390Q53401747-CAAC5D4E-BFF1-4B41-A1DD-3BA93E29A645Q53627337-8EBD42C4-B00B-4196-B08F-592431764457Q55043271-4AFE5BBF-0D7D-441D-8352-EFE0091F8F6FQ56547270-C075787D-21EA-4DE4-AF7D-1FDDDA688F8FQ57071396-6DA1B040-93D3-4F80-A2DA-F9BBC24A44C5Q57071461-00A318FF-11C6-4354-9E0B-F65C1A6E6CB1Q57212970-CAA91993-2EB6-4664-829C-B17413C65977Q57216378-A76326BD-131E-43C2-8367-51FED1BC4A49Q57225717-DFBCA996-4532-49E7-B92E-83EF28106089Q57227045-A620935B-8D78-48CE-9E7D-E11666D4EE20
P50
description
researcher
@en
wetenschapper
@nl
name
Jung Hye Kwon
@en
Jung Hye Kwon
@nl
type
label
Jung Hye Kwon
@en
Jung Hye Kwon
@nl
prefLabel
Jung Hye Kwon
@en
Jung Hye Kwon
@nl
P106
P31
P496
0000-0002-5965-3204